Skip to main content
Premium Trial:

Request an Annual Quote

Ciphergen Reports Rise in Revenues, Smaller Loss for Q1

NEW YORK, May 7 (GenomeWeb News) - Ciphergen Biosystems yesterday reported increased revenues and narrowed losses for the first quarter of the year.

 

The company's revenues totaled $15.5 million, up from $12.8 million in the first quarter of 2003.

 

R&D costs remained flast, at $6.2 million, compared to $6.4 million during the same quarter last year.

 

Ciphergen's net loss amounted to $7.5 million, or $.26 per share, down from $9.2 million, or $.34 per share, for the year-ago period.

 

As of March 31, Ciphergen had $39.6 million in cash, cash equivalents, and investments in marketable securities.

The Scan

Gone, But Now Reconstructed SARS-CoV-2 Genomes

In a preprint, a researcher describes his recovery of viral sequences that had been removed from a common database.

Rare Heart Inflammation Warning

The Food and Drug Administration is adding a warning about links between a rare inflammatory heart condition and two SARS-CoV-2 vaccines, Reuters reports.

Sandwich Sampling

The New York Times sent tuna sandwiches for PCR analysis.

Nature Papers Describe Gut Viruses, New Format for Storing Quantitative Genomic Data, More

In Nature this week: catalog of DNA viruses of the human gut microbiome, new dense depth data dump format to store quantitative genomic data, and more.